![]() |
Market Research Report
Product code
1084196
Oral Biologics Market, By Drug Class, By Disease Indication, By Distribution channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 |
Oral Biologics Market, By Drug Class, By Disease Indication, By Distribution channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 |
Published: May 26, 2022
Coherent Market Insights
Content info: 197 Pages
Delivery time: 2-3 business days
|
Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn's disease, and ulcerative colitis.
Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parenteral route and only guanylate cyclase-c agonist class of drug is approved oral biologics in market.
However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.
Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisition by key players is a major factor driving growth of the market. For instance, in February 2021, Biocon Limited announced merger with International Diabetes Federation (IDF), an insulin biosimilar company, and the merger focuses on the research and development of Biocon's biologics segment and promote the affordable access of insulin products manufactured by Biocon to the diabetes patients globally.
? By Drug Class
? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
? Hormone
? Recombinant Enzyme
? Guanylate Cyclase-C Agonist
? Somatostatin Analogue
? Others
? By Disease Indication
? Diabetes
? Hyperoxaluria
? Acromegaly
? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
? By Distribution Channel
? Hospital Pharmacies
? Retail Pharmacies
? Online Pharmacies
? By Country
? U.S.
? Canada
? By Drug Class
? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
? Hormone
? Recombinant Enzyme
? Guanylate Cyclase-C Agonist
? Somatostatin Analogue
? Others
? By Disease Indication
? Diabetes
? Hyperoxaluria
? Acromegaly
? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
? By Distribution Channel
? Hospital Pharmacies
? Retail Pharmacies
? Online Pharmacies
? By Country
? Brazil
? Mexico
? Argentina
? Rest of Latin America
? By Drug Class
? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
? Hormone
? Recombinant Enzyme
? Guanylate Cyclase-C Agonist
? Somatostatin Analogue
? Others
? By Disease Indication
? Diabetes
? Hyperoxaluria
? Acromegaly
? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
? By Distribution Channel
? Hospital Pharmacies
? Retail Pharmacies
? Online Pharmacies
? By Country
? Germany
? U.K.
? France
? Italy
? Spain
? Russia
? Rest of Europe
? By Drug Class
? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
? Hormone
? Recombinant Enzyme
? Guanylate Cyclase-C Agonist
? Somatostatin Analogue
? Others
? By Disease Indication
? Diabetes
? Hyperoxaluria
? Acromegaly
? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
? By Distribution Channel
? Hospital Pharmacies
? Retail Pharmacies
? Online Pharmacies
? By Country
? China
? India
? Japan
? Australia
? South Korea
? ASEAN
? Rest of Asia Pacific
? By Drug Class
? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
? Hormone
? Recombinant Enzyme
? Guanylate Cyclase-C Agonist
? Somatostatin Analogue
? Others
? By Disease Indication
? Diabetes
? Hyperoxaluria
? Acromegaly
? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
? By Distribution Channel
? Hospital Pharmacies
? Retail Pharmacies
? Online Pharmacies
? By Country
? GCC
? Israel
? Rest of Middle East
? By Drug Class
? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
? Hormone
? Recombinant Enzyme
? Guanylate Cyclase-C Agonist
? Somatostatin Analogue
? Others
? By Disease Indication
? Diabetes
? Hyperoxaluria
? Acromegaly
? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
? By Distribution Channel
? Hospital Pharmacies
? Retail Pharmacies
? Online Pharmacies
? By Country
? South Africa
? Central Africa
? North Africa
? Company Overview
? Product Portfolio
? Financial Overview
? Key Highlights
? Market Strategies
"*" marked represents similar segmentation in other categories in the respective section.